ArticleDrug design, development and therapy2026
Design, Synthesis and Biological Evaluation of New Oxazolidinone Antimicrobial Agents with Low Monoamine Oxidase A Inhibition.
Jie Zhang, Yuhua Hu, Hao Tian, Chuang Li, Zihe Liang, Yuhe Yuan, Fangfang Lai, Wenxuan Zhang, Song Wu
Abstract read
In one paragraphArticle in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Jie Zhang *State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China.ORCID 0009-0000-4671-0786 Yuhua Hu *State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China.ORCID 0009-0004-6004-2576 Hao TianState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China.ORCID 0009-0008-2599-7659 Chuang LiState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China.ORCID 0009-0003-4043-8955 Zihe LiangState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China.
Yuhe YuanState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China.
Fangfang LaiState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China.
Wenxuan ZhangState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China.
Song WuState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, People's Republic of China.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Introduction: Linezolid is an oxazolidinone antibacterial agent that acts by binding to the 23S rRNA of the bacterial 50S ribosomal subunit to inhibit protein synthesis and exhibits potent activity against Gram-positive pathogens and Methods: We applied a rational drug design strategy based on the distinct binding models of linezolid within human MAO-A and the ribosomal large subunit of Results & Discussion: This strategy led to the identification of compound Conclusion: These results closely validated our rational design strategy.
Indexed as
Anti-Bacterial AgentsDrug DesignMonoamine OxidaseMonoamine Oxidase InhibitorsOxazolidinonesDose-Response Relationship, DrugGram-Positive BacteriaHumansMicrobial Sensitivity TestsMolecular Docking SimulationMolecular StructureMycobacterium tuberculosisStaphylococcus aureusStructure-Activity RelationshipAnti-Bacterial AgentsMonoamine Oxidasemonoamine oxidase A, humanMonoamine Oxidase InhibitorsOxazolidinonesantibacterial activityhuman MAO-Aoxazolidinone derivativesrational drug designstructural modifications
Identifiers
PMID42404710
PMCPMC13332732
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390